Home
Companies
Catalysts
Deep Dives
MARITIME-OSA-1
PHASE3
ACTIVE
Drug:
MariTide
·
AMGN
Study Design
Design
Randomized, double-blind, placebo-controlled
NCT
NCT07225686
Treatment Arms
MariTide
SC (dose TBD)
Placebo
Placebo SC
Primary Endpoints
[{"id":"ahi","name":"Change in AHI (apnea-hypopnea index)","type":"PRIMARY","results":[],"description":"AHI measures severity of sleep apnea. Tirzepatide (SURMOUNT-OSA) showed ~50% AHI reduction. Population: patients ON PAP therapy."}]
Assessment
Recruiting since Dec 2025. Patients ON PAP therapy. Source: ClinicalTrials.gov NCT07225686
Background & Context
OSA tightly linked to obesity. GLP-1 class already approved in this indication (Zepbound for OSA).
Data from Supabase · Updated 2026-03-24